Cipher Pharmaceuticals Stock Performance
| CPH Stock | CAD 13.30 0.20 1.48% |
The firm shows a Beta (market volatility) of -0.44, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Cipher Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Cipher Pharmaceuticals is likely to outperform the market. At this point, Cipher Pharmaceuticals has a negative expected return of -0.17%. Please make sure to confirm Cipher Pharmaceuticals' skewness, and the relationship between the treynor ratio and daily balance of power , to decide if Cipher Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Cipher Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's technical indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
1 | Cipher Pharmaceuticals Eyes Nasdaq Listing After Strong Year - Finimize | 09/17/2025 |
2 | These 4 Measures Indicate That Cipher Pharmaceuticals Is Using Debt Extensively - simplywall.st | 10/10/2025 |
3 | Why pension funds invest in Cipher Pharmaceuticals Inc. stock - July 2025 Market Mood Risk Controlled Daily Trade Plans - newser.com | 10/15/2025 |
4 | Will Cipher Pharmaceuticals Inc. stock keep raising dividends - Weekly Trade Report Weekly Hot Stock Watchlists - newser.com | 10/22/2025 |
5 | Cipher Pharmaceuticals to Announce Q3 2025 Financial Results - TipRanks | 10/29/2025 |
6 | Cipher Pharmaceuticals Achieves Strong Q3 2025 Financial Performance - TipRanks | 11/06/2025 |
7 | When Moves Investors should Listen - news.stocktradersdaily.com | 11/10/2025 |
8 | Will Cipher Pharmaceuticals Inc. stock keep raising dividends - Insider Selling Stock Portfolio Risk Management - newser.com | 11/19/2025 |
| Begin Period Cash Flow | 39.8 M | |
| Total Cashflows From Investing Activities | -80 M |
Cipher |
Cipher Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,510 in Cipher Pharmaceuticals on August 22, 2025 and sell it today you would lose (180.00) from holding Cipher Pharmaceuticals or give up 11.92% of portfolio value over 90 days. Cipher Pharmaceuticals is producing return of less than zero assuming 2.4409% volatility of returns over the 90 days investment horizon. Simply put, 21% of all stocks have less volatile historical return distribution than Cipher Pharmaceuticals, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Cipher Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cipher Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cipher Pharmaceuticals, and traders can use it to determine the average amount a Cipher Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0703
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CPH |
Estimated Market Risk
| 2.44 actual daily | 21 79% of assets are more volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cipher Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cipher Pharmaceuticals by adding Cipher Pharmaceuticals to a well-diversified portfolio.
Cipher Pharmaceuticals Fundamentals Growth
Cipher Stock prices reflect investors' perceptions of the future prospects and financial health of Cipher Pharmaceuticals, and Cipher Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cipher Stock performance.
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.053 | ||||
| Profit Margin | 0.35 % | ||||
| Operating Margin | 0.39 % | ||||
| Current Valuation | 353.79 M | ||||
| Shares Outstanding | 25.37 M | ||||
| Price To Earning | 21.55 X | ||||
| Price To Book | 2.17 X | ||||
| Price To Sales | 6.85 X | ||||
| Revenue | 33.36 M | ||||
| Gross Profit | 37.2 M | ||||
| EBITDA | 11.87 M | ||||
| Net Income | 11.54 M | ||||
| Cash And Equivalents | 17.84 M | ||||
| Cash Per Share | 0.34 X | ||||
| Total Debt | 40.58 M | ||||
| Debt To Equity | 62.30 % | ||||
| Current Ratio | 1.06 X | ||||
| Book Value Per Share | 4.49 X | ||||
| Cash Flow From Operations | 19.55 M | ||||
| Earnings Per Share | 0.93 X | ||||
| Market Capitalization | 342.82 M | ||||
| Total Asset | 162.51 M | ||||
| Retained Earnings | 77.65 M | ||||
| Working Capital | 18.61 M | ||||
About Cipher Pharmaceuticals Performance
By examining Cipher Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Cipher Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Cipher Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 228.30 | 239.82 | |
| Return On Tangible Assets | 0.17 | 0.18 | |
| Return On Capital Employed | 0.06 | 0.06 | |
| Return On Assets | 0.07 | 0.07 | |
| Return On Equity | 0.11 | 0.12 |
Things to note about Cipher Pharmaceuticals performance evaluation
Checking the ongoing alerts about Cipher Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cipher Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cipher Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company has C$40.58 Million in debt which may indicate that it relies heavily on debt financing | |
| About 42.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Will Cipher Pharmaceuticals Inc. stock keep raising dividends - Insider Selling Stock Portfolio Risk Management - newser.com |
- Analyzing Cipher Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cipher Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Cipher Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cipher Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cipher Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cipher Pharmaceuticals' stock. These opinions can provide insight into Cipher Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.